{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:07:11Z","timestamp":1764133631010},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"DOI":"10.1093\/bjd\/ljad157","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T07:36:12Z","timestamp":1683531372000},"page":"9-10","source":"Crossref","is-referenced-by-count":1,"title":["Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?"],"prefix":"10.1093","volume":"189","author":[{"given":"William C","family":"Cranwell","sequence":"first","affiliation":[{"name":"Sinclair Dermatology"},{"name":"Dermatology Institute of Victoria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney D","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology"},{"name":"University of Melbourne , Melbourne, VIC , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"2023100915272745000_ljad157-B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100915272745000_ljad157-B2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","article-title":"Tapinarof cream 1%: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"2023100915272745000_ljad157-B3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2023100915272745000_ljad157-B4","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb, randomized, double-blind, vehicle-controlled, parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023100915272745000_ljad157-B5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase \u2013 signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023100915272745000_ljad157-B6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2023100915272745000_ljad157-B7","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023100915272745000_ljad157-B8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjd.21880","article-title":"How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?","volume":"187","author":"Lax","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023100915272745000_ljad157-B9"},{"key":"2023100915272745000_ljad157-B10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad157\/50603648\/ljad157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/1\/9\/51959336\/ljad157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/1\/9\/51959336\/ljad157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:30:43Z","timestamp":1696865443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/1\/9\/7156629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,8]]},"published-print":{"date-parts":[[2023,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad157","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,5,8]]}}}